Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.Blood · 2015
   Trial
2. Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.Hematology. American Society of Hematology. Education Program · 2020
   Article
3. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.Haematologica · 2014
   Article
4. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Current hematologic malignancy reports · 2013
   Review
5. MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.Haematologica · 2012
   Article

Corrections and comments

• Comment on
  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.2011
• Comment on
  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.2011

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as